1. Home
  2. DRUG vs VYGR Comparison

DRUG vs VYGR Comparison

Compare DRUG & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DRUG
  • VYGR
  • Stock Information
  • Founded
  • DRUG 2019
  • VYGR 2013
  • Country
  • DRUG United States
  • VYGR United States
  • Employees
  • DRUG N/A
  • VYGR N/A
  • Industry
  • DRUG Pharmaceuticals and Biotechnology
  • VYGR Biotechnology: Pharmaceutical Preparations
  • Sector
  • DRUG Health Care
  • VYGR Health Care
  • Exchange
  • DRUG Nasdaq
  • VYGR Nasdaq
  • Market Cap
  • DRUG 260.6M
  • VYGR 297.7M
  • IPO Year
  • DRUG N/A
  • VYGR 2015
  • Fundamental
  • Price
  • DRUG $37.65
  • VYGR $5.52
  • Analyst Decision
  • DRUG Strong Buy
  • VYGR Strong Buy
  • Analyst Count
  • DRUG 4
  • VYGR 9
  • Target Price
  • DRUG $84.33
  • VYGR $15.53
  • AVG Volume (30 Days)
  • DRUG 91.2K
  • VYGR 338.7K
  • Earning Date
  • DRUG 12-31-2024
  • VYGR 02-26-2025
  • Dividend Yield
  • DRUG N/A
  • VYGR N/A
  • EPS Growth
  • DRUG N/A
  • VYGR N/A
  • EPS
  • DRUG N/A
  • VYGR 0.47
  • Revenue
  • DRUG N/A
  • VYGR $163,784,000.00
  • Revenue This Year
  • DRUG N/A
  • VYGR N/A
  • Revenue Next Year
  • DRUG N/A
  • VYGR N/A
  • P/E Ratio
  • DRUG N/A
  • VYGR $11.78
  • Revenue Growth
  • DRUG N/A
  • VYGR 3.40
  • 52 Week Low
  • DRUG $0.93
  • VYGR $4.99
  • 52 Week High
  • DRUG $79.02
  • VYGR $10.66
  • Technical
  • Relative Strength Index (RSI)
  • DRUG 55.50
  • VYGR 41.99
  • Support Level
  • DRUG $28.21
  • VYGR $5.32
  • Resistance Level
  • DRUG $38.00
  • VYGR $5.76
  • Average True Range (ATR)
  • DRUG 2.86
  • VYGR 0.28
  • MACD
  • DRUG 0.45
  • VYGR 0.03
  • Stochastic Oscillator
  • DRUG 96.42
  • VYGR 35.05

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: